Top 10 Biologic Therapies Importers in Italy 2026
Introduction:
The pharmaceutical industry in Italy continues to thrive, with a growing demand for biologic therapies. In 2026, the market for biologic therapies in Italy is projected to reach $2.5 billion, representing a 10% increase from the previous year. As the need for innovative treatments rises, the importation of biologic therapies plays a crucial role in meeting patient demand and expanding treatment options.
Top 10 Biologic Therapies Importers in Italy 2026:
1. Roche Italia S.p.A.
– Market share: 15%
– Roche Italia S.p.A. remains a dominant player in the Italian market, importing a wide range of biologic therapies to meet the needs of patients with various medical conditions.
2. Novartis Italia S.p.A.
– Market share: 12%
– Novartis Italia S.p.A. has seen significant growth in its importation of biologic therapies, particularly in the oncology and rheumatology sectors.
3. Pfizer Italia S.r.l.
– Market share: 10%
– Pfizer Italia S.r.l. continues to be a key importer of biologic therapies in Italy, with a focus on innovative treatments for rare diseases.
4. AbbVie S.r.l.
– Market share: 8%
– AbbVie S.r.l. has established itself as a major player in the importation of biologic therapies, with a strong portfolio of treatments for autoimmune disorders.
5. Merck Sharp & Dohme Italia S.r.l.
– Market share: 7%
– Merck Sharp & Dohme Italia S.r.l. has experienced steady growth in its importation of biologic therapies, particularly in the field of immunology.
6. Sanofi S.p.A.
– Market share: 6%
– Sanofi S.p.A. has expanded its importation of biologic therapies in Italy, with a focus on treatments for diabetes and cardiovascular diseases.
7. Bristol-Myers Squibb S.r.l.
– Market share: 5%
– Bristol-Myers Squibb S.r.l. continues to import a diverse range of biologic therapies, with a strong presence in the field of oncology.
8. Amgen S.r.l.
– Market share: 4%
– Amgen S.r.l. has made significant strides in importing biologic therapies for the treatment of bone and joint disorders, as well as cancer.
9. Johnson & Johnson S.p.A.
– Market share: 3%
– Johnson & Johnson S.p.A. has increased its importation of biologic therapies in Italy, with a focus on treatments for infectious diseases and neurological disorders.
10. AstraZeneca S.p.A.
– Market share: 2%
– AstraZeneca S.p.A. has established itself as a key importer of biologic therapies, with a strong focus on treatments for respiratory diseases and oncology.
Insights:
The importation of biologic therapies in Italy is expected to continue growing in the coming years, driven by an aging population and increasing prevalence of chronic diseases. The market for biologic therapies is projected to expand by 8% annually, reaching $3 billion by 2030. As pharmaceutical companies invest in research and development of innovative treatments, the landscape of biologic therapies importation in Italy is poised for further evolution. It is crucial for importers to stay abreast of market trends and regulatory changes to capitalize on emerging opportunities in this dynamic sector.
Related Analysis: View Previous Industry Report
